Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesRadiology/Diagnostic ImagingAetna Breast Biopsy Coverage Update | OpenPayer
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentAetnaPolicy 0269

    Breast Biopsy Procedures

    Customize your policy alerts

    Sign up for Aetna Policy 0269 alerts

    Get alerted when Policy 0269 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines Aetna's coverage stance for minimally invasive image-guided breast biopsy procedures and related localization techniques for non-palpable or difficult-to-palpate breast abnormalities; applies to Aetna members and providers performing breast biopsy and localization procedures.

    Policy Summary
    PayerAetna
    PolicyBreast Biopsy Procedures
    Policy CodePolicy 0269
    Change TypeNo material changes
    Effective DateN/A
    Last ReviewApr 26, 2023
    Next Review DateN/A
    Key ActionDocument lesion characteristics (non-palpable, deep, mobile, small, or clustered microcalcifications) and the image-guidance method to support medical necessity when submitting for authorization or claims.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    6listed minimally invasive image-guided biopsy procedures considered medically necessary
    4procedures considered experimental/investigational (examples listed)
    07/16/1998effective date (document history)
    04/26/2023last review date
    03/14/2024next review date

    Coverage Criteria — Image-guided Breast Biopsy and Localization

    inv-09: MIB to predict pCR — evidence summary

    Image-guided minimally invasive biopsy (MIB) to predict pathologic complete response (pCR) after neoadjuvant systemic therapy (NST) — Evidence summary:

    Multiple prospective and multicenter cohort studies and meta-analyses have evaluated the accuracy of image-guided MIB (primarily ultrasound-guided core biopsy) to identify breast pCR following NST. Early feasibility data (MICRA) and subsequent prospective studies demonstrated that obtaining representative post‑NST core samples is feasible but that false-negative rates (FNRs) are substantial in many series and vary by imaging response and tumor subtype.
    Van der Noordaa et al (MICRA trial initial feasibility) reported that US-guided post‑NST biopsy was feasible; however, larger validation cohorts were required to determine FNR and clinical utility.
    van Loevezijn et al (prospective multicenter single‑arm study) of pre‑surgical US-guided 14‑G core biopsies in patients with MRI rCR/rPR obtained a FNR of 37 % (29/78 FN among those with residual disease) and concluded MIB in their protocol was not accurate enough to reliably identify breast pCR; surgery could not be safely omitted based on biopsy results.
    Policy Summary
    PayerAetna
    PolicyBreast Biopsy Procedures
    Policy CodePolicy 0269
    Change TypeNo material changes
    Effective DateN/A
    Last ReviewApr 26, 2023
    Next Review DateN/A
    Key ActionDocument lesion characteristics (non-palpable, deep, mobile, small, or clustered microcalcifications) and the image-guidance method to support medical necessity when submitting for authorization or claims.
    SourceLink
    On This Page
    Coverage Criteria — Image-guided Breast Biopsy and LocalizationCovered IndicationsCoding — CPT/HCPCS/ICD-10Provider Actions — Prior Authorization, Documentation, BillingPrior Authorization NotesContrast and Imaging Guidance RulesNot Covered / Experimental ProceduresBackgroundDefinitionsFrequency LimitsRevision History and References
    Li et al (2020) meta‑analysis of 9 trials (1,030 patients) reported pooled sensitivity 0.72 (95 % CI: 0.61–0.81) and specificity 0.99 (95 % CI: 0.89–1.00). Heterogeneity existed across studies; trials that did not restrict inclusion to clinical complete responders had higher accuracy than those limited to clinical CR.
    Key limitations across studies include variable biopsy techniques (gauge, number of cores), variable imaging guidance and response assessment criteria (MRI vs ultrasound), small sample sizes in several trials, and heterogeneity in timing of biopsies and patient/tumor characteristics (molecular subtype impacts FNR).
    Overall interpretation: Current evidence indicates that image-guided MIB can identify pCR in some patients, but sensitivity is insufficient and FNRs are unacceptably high in many series to allow routine omission of surgical resection after NST. Standardization of biopsy technique (marker placement, number/size of cores, imaging correlation), patient selection, and prospective validation in larger trials are required before MIB can replace surgical pathology to confirm pCR.

    inv-10: Intra‑operative margin assessment (MarginProbe) — evidence summary

    Intra‑operative margin assessment (MarginProbe) — Evidence summary:

    MarginProbe is a hand‑held radiofrequency spectroscopy device FDA‑cleared in 2013 to assess margins on excised lumpectomy specimens intra‑operatively by detecting dielectric differences between normal and malignant tissue.
    Several single‑center retrospective studies and comparative analyses have associated MarginProbe use with reductions in positive margin rates and re‑excision rates. For example, Coble and Reid (2017) reported a reduction in re‑excision rate from 15.1 % to 6.6 % and a 32 % reduction in overall tissue volume removed after instituting a MarginProbe‑guided targeted shaving approach compared with prior full cavity shaving.
    Kupstas et al (retrospective chart review) reported a 50 % reduction in re‑lumpectomy rate (p = 0.039) after adoption of MarginProbe without increasing total tissue volume resected.
    Systematic reviews (Gray et al 2018) found that MarginProbe and cavity‑shave techniques both lower positive margin rates, although there may be tradeoffs such as potential negative cosmetic effects and variable quality of evidence across studies.
    Contrasting assessments: The BlueCross BlueShield Technology Evaluation Center (TEC, 2013) concluded that radiofrequency spectroscopy for intraoperative margin assessment did not meet TEC criteria. UpToDate (Chagpar, 2019) notes studies associating MarginProbe with lower positive margin and re‑excision rates but highlights disadvantages including capital and disposable probe costs and lack of evidence that MarginProbe is superior to other strategies (e.g., cavity shave margins) in all settings.
    Limitations and clinical considerations include single‑center and retrospective study designs, variability in operative workflow and surgeon technique, capital and per‑procedure costs for device and disposables, and absence of definitive randomized multicenter data demonstrating consistent clinical outcome improvements across practice settings.
    Overall interpretation: Evidence suggests MarginProbe can reduce positive margin and re‑excision rates in some practice settings as an adjunct to standard margin‑assessment techniques, but heterogeneity of data, cost considerations, and incomplete demonstration of benefit over established approaches mean its routine, unconditional adoption is not yet supported; clinical judgment and site‑specific assessment of benefit, workflow, and cost are recommended.

    Covered Indications

    Coding — CPT/HCPCS/ICD-10

    Covered CPT CodesCPTCovered
    19081Biopsy, breast, with placement of breast localization device(s) (eg, clip, metallic pellet), when performed, and imaging of the biopsy specimen, when performed, percutaneous; first lesion, including stereotactic guidance.
    19082Each additional lesion, including stereotactic guidance (List separately in addition to code for primary procedure).
    19083Biopsy, breast, with placement of breast localization device(s) (eg, clip, metallic pellet), when performed, and imaging of the biopsy specimen, when performed, percutaneous; first lesion, including ultrasound guidance.
    19084Each additional lesion, including ultrasound guidance (List separately in addition to code for primary procedure).
    19085Biopsy, breast, with placement of breast localization device(s) (eg, clip, metallic pellet), when performed, and imaging of the biopsy specimen, when performed, percutaneous; first lesion, including magnetic resonance guidance.
    19086Each additional lesion, including magnetic resonance guidance (List separately in addition to code for primary procedure).
    19281Placement of breast localization device(s) (eg, clip, metallic pellet, wire/needle, radioactive seeds), percutaneous; first lesion, including mammographic guidance.
    19282Each additional lesion, including mammographic guidance (List separately in addition to code for primary procedure).
    19283Placement of breast localization device(s) (eg, clip, metallic pellet, wire/needle, radioactive seeds), percutaneous; first lesion, including stereotactic guidance.
    19284Each additional lesion, including stereotactic guidance (List separately in addition to code for primary procedure).
    1–10 of 23
    1/3
    Not Covered CPT CodesCPTNot Covered
    0546TRadiofrequency spectroscopy, real time, intraoperative margin assessment, at the time of partial mastectomy, with report.
    763763D rendering with interpretation and reporting of computed tomography, magnetic resonance imaging, ultrasound, or other tomographic modality with image postprocessing under concurrent supervision; not requiring image postprocessing on an independent workstation.
    763773D rendering requiring image postprocessing on an independent workstation.
    HCPCS Covered CodesHCPCSCovered
    C7501Percutaneous breast biopsies using stereotactic guidance, with placement of breast localization device(s) (eg, clip, metallic pellet), when performed, and imaging of the biopsy specimen, when performed, all lesions unilateral and bilateral (for single lesion biopsy, use appropriate code).
    C7502Percutaneous breast biopsies using magnetic resonance guidance, with placement of breast localization device(s) (eg, clip, metallic pellet), when performed, and imaging of the biopsy specimen, when performed, all lesions unilateral or bilateral (for single lesion biopsy, use appropriate code).
    G0279Diagnostic digital breast tomosynthesis, unilateral or bilateral (List separately in addition to G0204 or G0206).
    ICD-10 CodesICD-10
    C50.011 - C50.929Malignant neoplasm of breast.
    C79.2Secondary malignant neoplasm of skin [of breast].
    C79.81Secondary malignant neoplasm of breast.
    D05.00 - D05.92Carcinoma in situ of breast.
    D24.1 - D24.9Benign neoplasm of breast.
    D48.60 - D48.62Neoplasm of uncertain behavior of breast.
    N60.01 - N60.99Benign mammary dysplasias.
    N63.0 - N63.42Unspecified lump in unspecified breast [breast nodules].
    R92.0 - R92.8Abnormal and inconclusive findings on diagnostic imaging of breast.
    Codes mentioned elsewhere in evidence sectionsmixed
    No codes listed
    Covered CPT Codes (additional mentions)CPT
    No codes listed
    Lesion size threshold — clinical thresholds
    Lesion size thresholdLesions described as small (less than 2 cm) may warrant image-guided biopsy
    ContextThreshold applies to non-palpable or difficult-to-palpate lesions (deep, mobile, clustered microcalcifications) identified by mammography
    Palpable lesions noteFor larger, fixed, palpable lesions, image guidance is not medically necessary; palpation-guided biopsy is sufficient
    Seeds per procedure — typical seed usage
    Typical seeds used per procedureMajority of RSL procedures utilized 1 seed (86% in the McGhan series)
    Total seeds deployed (example series)1,148 seeds deployed in 1,000 procedures (McGhan et al) — demonstrates occasional use of >1 seed
    Timing of placement76% of seeds were placed greater than or equal to 1 day before surgery in cited series
    Minimum biopsy cores — study-suggested thresholds
    Minimum cores associated with high NPVObtaining ≥5 biopsy cores in a select prospective study (with strict MRI criteria) resulted in 100% NPV and accuracy
    Typical core counts in feasibility trialsMedian of 8 biopsies obtained (range 4–9) reported in MICRA feasibility series; median representative biopsies 4 (range 1–8)
    Clinical implicationHigher core counts plus stringent MRI selection improved negative predictive value but larger validation studies are needed
    Maximum recommended implantation depth — device recommendation and exceptions
    Manufacturer recommended maximum implantation depthMarker implantation depth limited to up to 3 cm per manufacturer recommendation
    Reported exceptionsIndividual reports noted successful detection at deeper implantations (3.3 cm and 5.0 cm) with probe palpation assistance
    Operational limits and compatibilityDeeper implantation may reduce detection; probe recalibration, interference with paramagnetic instruments, and MRI bloom artifact are noted practical limits

    Provider Actions — Prior Authorization, Documentation, Billing

    Prior Authorization

    Prior authorization for covered biopsy/localization codes

    Prior authorization may be required for covered biopsy and localization procedures per usual plan rules. When submitting for authorization, include the clinical indication and planned CPT/HCPCS codes for the biopsy or localization procedure.

    • Affected covered codes include CPT 19081–19086, 19281–19286 and related diagnostic mammography/MRI codes (e.g., 77046–77047, 77053–77067) and HCPCS C7501, C7502, G0279 when selection criteria are met.
    • Obtain prior authorization according to standard Aetna procedures when billing these covered biopsy/localization services.
    Prior Authorization

    Prior authorization for magnetic seed localization (operational note)

    Newer localization technologies such as magnetic seed localization (Magseed) or SAVI SCOUT may have operational prior-authorization requirements or documentation expectations. Check payer-specific prior authorization pathways for these technologies and include device type and placement timing in the request.

    • Operational note: magnetic seeds (e.g., Magseed) and non-wire, non-incision (NWNI) reflector systems can be placed days before surgery — document placement date relative to surgery.
    • Provide device manufacturer/name (e.g., Magseed, Savi Scout), placement technique, and intended surgical plan when requesting authorization.
    Billing Rule

    Non-covered CPT/HCPCS codes

    Certain codes and proprietary device billing may not be covered for the indications described in this policy. Billing unsupported codes can trigger denials.

    • HCPCS / proprietary or unlisted device entries for some systems may have no specific covered code (e.g., entries noting Savi Scout / magseed with no specific CPT) — submit appropriate supporting documentation and prior authorization.
    • Examples of not-covered or unspecified-code situations should be confirmed with the plan before billing to avoid denials.
    Note

    Not applicable content in this excerpt

    Not applicable: This excerpt does not establish global prior-authorization exclusions, step-therapy requirements, or other utilization-management mandates beyond the specific notes above. Providers should follow standard Aetna prior-authorization processes where applicable.

    • No step-therapy requirements are specified in this excerpt.
    • No blanket prior-authorization prohibition or universal coverage exclusion is stated in this excerpt.
    Documentation Required

    Clinical documentation to support necessity

    Document clinical information that supports medical necessity when requesting authorization or when billing: include lesion characteristics, imaging findings, targeted lesion laterality, and rationale for the chosen biopsy/localization method.

    • Lesion size, palpability, imaging modality findings (mammogram, MRI, ultrasound) and reason image-guidance is required.
    • Planned procedure (CPT/HCPCS), device to be used (clip, seed, reflector), and expected number of lesions to be sampled/localized.
    Documentation Required

    Suggested documentation elements from clinical studies

    When available, include study-derived or consensus-recommended documentation elements to strengthen the record: informed consent, placement confirmation imaging, number and type of cores or seeds, and pathology correlation.

    • Informed consent specific to the localization/biopsy device and procedure.
    • Placement verification: radiographic or ultrasound image documenting marker/seed/reflector position and specimen radiograph confirming retrieval when applicable.
    • Device details: type, manufacturer/model, lot number if available, date/time of placement, and any migration noted.
    Documentation Required

    Documentation elements for MIB after NST

    For image-guided minimally invasive biopsy (MIB) performed after neoadjuvant systemic therapy (NST), include protocol-specific elements used in trials that evaluated pCR prediction: number of cores obtained, imaging response criteria, and correlation with surgical pathology.

    • Document pre-NST marker placement, MRI/US response (rCR/rPR), and imaging criteria used to select MIB.
    • Record number of cores obtained (trial medians/ranges reported: median 8 cores, representative biopsies median 4), biopsy guidance modality, and any technical limitations (e.g., marker not visualized).
    • Note that trials reported false-negative rates and that MIB alone may not reliably permit omission of surgery; document counseling and rationale if used for management decisions.
    Documentation Required

    Documentation suggested by study outcomes

    Studies of newer localization and intraoperative margin-assessment techniques recommend documenting localization method, seed/reflector placement details (timing, depth, migration), MarginProbe or intraoperative assessment use, and margin outcomes to support clinical decisions and billing.

    • For magnetic seed/Magseed: placement depth, distance from target on imaging, any migration, and retrieval confirmation.
    • For SAVI SCOUT or reflector systems: placement date relative to surgery, imaging confirmation, number of reflectors (if bracketing), and specimen verification.
    • For MarginProbe: indication for use, device readings that prompted additional shavings, and resulting margin and re-excision outcomes.
    Step Therapy

    Step approach for intraoperative margin assessment

    Step approach for intraoperative margin assessment: when MarginProbe or targeted shaving is used, document the intraoperative decision process, device findings that guided additional tissue removal, and comparison of device-directed shavings versus full-cavity shaving to support the operative record and coding.

    • Record whether MarginProbe prompted targeted shavings and the extent (number/volume) of additional tissue removed.
    • Document final margin status on pathology and any subsequent re-excision recommendations.
    • Include that use of MarginProbe is an adjunct to — not a replacement for — standard surgical judgment.

    Prior Authorization Notes

    Billing Rule

    Bill using the covered CPT/HCPCS codes and document selection criteria

    When any listed modality is billed, ensure the claim uses the covered CPT/HCPCS codes listed in the policy and that selection criteria are documented, since billing should reflect the covered codes.

    • Covered CPT examples include 19081–19086 and 19281–19288.
    • Covered HCPCS examples include C7501, C7502, and G0279.
    Prior Authorization

    No prior authorization specified for SAVI SCOUT in excerpt

    The excerpt does not specify a prior authorization requirement for the SAVI SCOUT system.

    Prior Authorization

    No prior authorization specified for SAVI SCOUT/RSL/ROLL/MarginProbe

    No explicit prior authorization requirements are provided in the cited excerpts for SAVI SCOUT, RSL, ROLL, or MarginProbe.

    Prior Authorization

    Magseed/novel devices: provide clinical rationale and placement documentation if authorization required

    Use of Magseed and other novel localization devices may require prior authorization depending on payer local policy; if requested, provide clinical rationale and documentation of device placement and intended surgical plan.

    • Magseed shown to have high placement and localization success in pooled analyses.
    • If authorization needed, include evidence of placement, intended use, and institutional preference.
    Prior Authorization

    No explicit prior-authorization thresholds for magnetic seeds in excerpt

    No explicit prior authorization thresholds or numeric limits for magnetic seed localization or other NWNI devices are specified in this excerpt.

    Contrast and Imaging Guidance Rules

    Billing Rule

    Use MRI-guidance codes (19085/19086, 19287/19288, 77021) when MRI guidance criteria are met

    MRI-guided biopsy/localization codes are listed (e.g., 19085/19086, 19287/19288, 77021) and should be used when MRI guidance selection criteria are met.

    • Use MRI guidance CPT codes for procedures performed under MRI guidance.
    • Document that MRI guidance selection criteria were met when billing these codes.
    Billing Rule

    No contrast-specific billing rules for tomosynthesis/biopsy in excerpt

    The policy excerpts do not provide contrast-specific billing rules for tomosynthesis or biopsy procedures.

    Billing Rule

    MRI artifact considerations for magnetic seeds; no contrast rules specified

    MRI compatibility limitations for magnetic seeds are noted (bloom artifact up to 6 cm); no specific contrast billing rules are provided for NWNI devices in the excerpt.

    • Magseed compatible with MRI but can produce a bloom artifact up to 6 cm.

    Not Covered / Experimental Procedures

    PET‑guided breast biopsy techniques (for example, Naviscan) and three‑dimensional volumetric imaging/reconstruction methods are listed in the policy inventory as experimental, investigational, and not covered for the indications described. These techniques are flagged as not covered due to insufficient evidence of effectiveness.

    The policy inventory and coding sections repeat that PET‑guided breast biopsy (Naviscan) is considered experimental/investigational and not covered for the listed indications; related imaging reconstruction techniques are similarly identified as not covered.

    Additional experimental image‑guided localization and imaging reconstruction techniques are identified in the policy as investigational and not covered. The bulletin’s not‑covered lists and inventory reference these novel approaches as lacking established effectiveness.

    The bulletin states that routine use of digital breast tomosynthesis (DBT) as a primary screening tool and tomosynthesis‑guided biopsy as standard practice is not supported by current evidence in the cited literature, and these uses are identified as not covered/unsupported for routine implementation pending higher‑quality outcome data.

    Experimental PET‑guided biopsy and 3‑D volumetric imaging/reconstruction techniques are listed repeatedly in the inventory and not‑covered sections as examples of procedures considered investigational.

    The policy inventory and not‑covered entries include experimental PET‑guided biopsy and 3‑D imaging reconstruction methods among techniques classified as investigational/not covered, reflecting the absence of sufficient evidence to support routine clinical use.

    Background

    Minimally invasive image‑guided breast biopsies are described as alternatives to needle localization core surgical biopsy for non‑palpable or difficult‑to‑palpate lesions. These methods generally offer shorter procedure time, less patient discomfort and cosmetic deformity, reduced mammographic artifact, and cost advantages; large‑core (11‑ or 14‑gauge) biopsies are preferred over fine‑needle aspiration because they provide more adequate tissue for pathology and allow differentiation of in‑situ from invasive carcinoma.

    Definitions

    Lesion descriptors — non-palpable or difficult-to-palpate lesions
    Non-palpable or difficult-to-palpate lesions (definition)Lesions identified by mammography that are non-palpable or difficult to palpate because they are deep, mobile, small (<2 cm), or composed of clustered microcalcifications
    Imaging contextThese lesion descriptors are the typical indications for image-guided minimally invasive biopsy as alternatives to needle localization surgical biopsy
    Palpation-guidance exceptionFor larger, fixed, palpable lesions, palpation-guided biopsy is considered sufficient and image guidance is not medically necessary
    ABBI — Advanced Breast Biopsy Instrument definition
    ABBI — definitionAdvanced Breast Biopsy Instrument (ABBI): a stereotactically guided device allowing excision of a 2-cm core of breast tissue
    Use caseListed as one of the minimally invasive image-guided biopsy alternatives to needle localization core surgical biopsy for non-palpable lesions
    Regulatory/context noteIncluded in Aetna’s list of medically necessary procedures when indications are met
    RSL — Radioactive Seed Localization definition and context
    RSL — definitionRadioactive Seed Localization: placement of a small radioactive seed into a non-palpable breast lesion preoperatively to guide surgical excision
    Clinical outcomes (example)In McGhan series (1,000 procedures) negative margin at first operation was 97% for invasive carcinoma and DCIS; low complication and migration rates reported
    Comparative contextSystematic reviews/meta-analyses report RSL as comparable or superior to wire-guided localization for margin status and re-operation rates in pooled analyses
    RGL / ROLL — Radio-guided localization definitions
    RGL / ROLL — definitionRadio-guided localization (RGL) / Radio-guided occult lesion localization (ROLL): techniques using radioguidance to localize non-palpable lesions for surgical excision
    Evidence summarySystematic reviews combining ROLL and RSL studies found lower positive margin rates and fewer re-operations for RGL versus wire localization in pooled analyses
    Study volumeLiterature reviews identified multiple studies (eg, 52 studies on ROLL/RSL with 27 meeting inclusion criteria in one review)
    DBT / Tomosynthesis — definition and imaging description
    DBT / Tomosynthesis — definitionDigital breast tomosynthesis (3-D mammography) acquires thin-slice images via an arc acquisition and reconstructs cross-sectional slices to produce thin-section views of the breast
    Biopsy useDBT can be used to guide stereotactic or tomosynthesis-guided biopsies; tomosynthesis-guided biopsy is considered an acceptable alternative to mammographically guided biopsy for medically necessary indications
    Evidence caveatPublished peer-reviewed literature has not definitively established accuracy and clinical utility for all DBT-guided procedures; evidence is evolving
    SAVI SCOUT — device/system definition and mechanism
    SAVI SCOUT — definitionSAVI SCOUT Surgical Guidance System: an FDA-cleared, non-radioactive system using an implantable electromagnetic wave reflector and a detector hand-piece/console to provide real-time guidance for localization and excision of non-palpable breast lesions
    Placement timingReflectors can be placed up to 7 days before surgery in reported pilot studies
    Clinical evidencePilot and feasibility studies report high successful placement and retrieval rates with favorable margin and re-excision outcomes, though larger trials are ongoing
    SAVI SCOUT (SCOUT) — alternate definition entry
    SCOUT (alternate entry)SCOUT (SAVI SCOUT): a non-radioactive, FDA-cleared implantable infrared/electromagnetic reflector system detected by a handheld detector to guide excision of non-palpable breast lesions
    Key pilot findingsIn a 50-patient pilot, reflectors placed under mammographic or ultrasound guidance were removed successfully in all patients with high clear margin rates among cancers
    Operational noteUsed as an alternative to wire localization; larger multicenter trials underway to validate pilot results
    Radioactive Seed Localization (RSL) — additional definition context
    RSL — additional contextRSL uses a small radioactive iodine seed (eg, I-125) placed into the lesion preoperatively; series report high success, low migration, and favorable margin outcomes
    Operational advantagesRSL can be placed days before surgery and has been reported as easy to learn with low incidence of positive/close margins in large single-institution series
    Comparative evidenceMeta-analyses and pooled studies indicate RSL may reduce positive margins and re-operations compared with wire-guided localization
    MarginProbe — device definition (intraoperative dielectric spectroscopy)
    MarginProbe — device definitionMarginProbe: a handheld intraoperative device using dielectric spectroscopy (radiofrequency/dielectric properties) to assess excised specimen margins and guide targeted additional shavings
    Intended useIntended to reduce positive margins at initial surgery and decrease need for re-excision by testing specimen margins intraoperatively
    Regulatory statusFDA-approved (2013) for intraoperative margin assessment
    RSL / ROLL — combined definition entry
    RSL / ROLL — combined entryRSL/ROLL: radio-guided localization techniques using radioactive markers or radiotracers to mark non-palpable breast lesions for surgical excision
    Evidence summarySystematic reviews and meta-analyses report comparable or improved margin and re-operation outcomes versus wire localization in pooled analyses
    Clinical implementationUsed as alternatives to wire-guided localization; selection may depend on institutional practice and resources
    MarginProbe — additional definition entry
    MarginProbe — additional entryMarginProbe is a handheld probe applying dielectric spectroscopy to excised specimens to detect malignant tissue near margins and guide immediate additional excision
    Reported outcomesSingle-center series reported reductions in re-excision rates (eg, 57% reduction) and reduced specimen volume compared with full cavity shaving
    Evidence limitationsSystematic reviews note mixed evidence and potential trade-offs in cosmetic outcomes and cost; further studies recommended
    Magseed — magnetic seed localization definition
    Magseed — definitionMagseed: a magnetic seed localization system (non‑radioactive) that uses an inducible magnetic marker detected by a handheld probe (eg, Sentimag) for pre-operative localization of non-palpable breast lesions
    Performance metricsPooled analyses report high placement (94.42%) and localization (99.86%) success with low migration and retrieval failures in most series
    LimitationsManufacturer recommends implantation depth up to 3 cm; MRI bloom artifact (up to 6 cm) and probe interference with paramagnetic instruments are documented concerns
    MIB — definition for image-guided minimally invasive biopsy
    MIB — definitionImage-guided minimally invasive biopsy (MIB): ultrasound- or image-guided core needle or vacuum-assisted biopsy targeting the tumor bed after neoadjuvant therapy to assess for pathologic complete response
    Clinical roleUsed investigationally to predict pCR after neoadjuvant systemic therapy; current evidence shows variable false-negative rates and limited accuracy to omit surgery
    Procedure detailsStudies report variable numbers of cores (median 4–8) and emphasize correlation with MRI response and marker placement
    Magnetic seed localization — Magseed / magnetic seed definition
    Magnetic seed localization — definitionMagnetic seed localization (Magseed): a non‑radioactive localization method using a magnetic seed and handheld detector to guide surgical excision; can be implanted days before surgery
    Comparative findingsPooled studies report localization and retrieval success comparable to wire-guided localization with similar re-excision/clear margin rates
    Practical notesLimitations include manufacturer depth recommendation (≤3 cm), MRI artefact, probe recalibration and instrument interference
    NWNI — Non-wired non-ionizing techniques definition
    NWNI — definitionNon‑wired non‑ionizing (NWNI) techniques: novel localization approaches (eg, reflectors, magnetic seeds, RFID tags) that do not use wires or ionizing radiation and can be placed days before surgery
    Clinical advantagesAllow decoupling of localization from surgery, high localization success, and potential logistical benefits compared to wire or radioactive methods
    Evidence statusPromising results in observational studies and pooled analyses but randomized trials and longer-term outcome data are limited
    3D-SI — Three-dimensional surface imaging systems definition (Axis Three, Vectra XT examples)
    3D-SI — definitionThree-dimensional surface imaging (3D‑SI) systems: noninvasive scanners (examples: Axis Three, Vectra XT) used to calculate breast volume and symmetry for pre-operative planning and cosmetic assessment
    PerformanceValidation studies show excellent to substantial reliability versus water-displacement and MRI for volume measurement; intra- and inter-observer variability generally low
    Clinical utilityUseful for reconstruction planning and objective cosmetic outcome assessment but requires further validation in larger cohorts
    Definitions (link) — reference to master definitions link
    Definitions resource linkPolicy links to a master Definitions page for additional terminology and device descriptions
    Policy contextRefer to the Definitions link in the policy history for full list of terms used throughout the bulletin
    LocationDefinitions accessible via the policy’s Definitions link (see Policy History section)

    Frequency Limits

    DBT — frequency/limit entry
    DBT frequency/limit entryDigital breast tomosynthesis (DBT) listed under frequency limits section of policy (no numeric frequency specified in excerpt)
    Policy noteExcerpt does not provide a numeric limit or interval for DBT frequency; billing follows listed CPT/HCPCS codes and payer rules
    Evidence contextDBT is FDA-approved as adjunct to standard mammography; large prospective outcome trials for routine replacement not yet established
    Frequency limit — policy inventory entry
    Frequency limit — entryPolicy includes an additional frequency-limits key-value entry without explicit numeric values in provided excerpt
    InterpretationNo explicit numeric frequency or periodicity provided in these chunks; follow payer billing rules and listed procedure codes
    Actionable guidanceWhen frequency limits are required, consult full policy or payer prior authorization rules for any modality-specific limits

    Revision History and References

    The policy history and review metadata are provided in the bulletin. The most recent review date shown is 04/26/2023, the effective date is listed as 07/16/1998, and the next scheduled review is noted as 03/14/2024.